Whether you are a cancer patient undergoing chemotherapy or a biopharmaceutical company with a novel compound, our assays can make a world of difference.

We are the leader in the design and development of  pharmacogenomic (PGx) assays of chemotherapeutics. Our  assays are used  to guide chemotherapy selection in advanced-stage cancer patients and to simulate clinical trials in Model Based Drug Development.  To date, we have developed over 80 PGx assays of the most widely used chemotherapeutic drugs to treat over 85% of cancer patients with solid tumors. Our assays are currently being used in multiple clinical trials and research studies in the U.S and Europe.

For individual patients, our PGx assays are used  to guide-chemotherapy selection in gastrointestinal, breast, lung  and pediatric cancers.  For most patients, we can evaluate a broad range of chemotherapeutic agents using a simple blood test to determine the most effective agents, either alone or in combination, for their treatment.

For biopharmaceutical companies, our assays are used  in Model Based Drug Development to simulate clinical trials and develop patient enrichment strategies.